The use of antiangiogenic drugs, such as bevacizumab, represents an appealing intervention against cancer. However, not all malignancies are equally responsive to such treatment. Recent trials demonstrate the efficacy of this drug for advanced-stage cervical cancer and, despite limitations, bevacizumab provides an important clinical respite for most patients with progressive glioblastoma.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Cohen, M. H. et al. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist 14, 1131–1138 (2009).
Chinot, O. L. et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N. Engl. J. Med. 370, 709–722 (2014).
Gilbert, M. R. et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N. Engl. J. Med. 370, 699–708 (2014).
Tewari, K. S. et al. Improved survival with bevacizumab in advanced cervical cancer. N. Engl. J. Med. 370, 734–743 (2014).
Clere, N. et al. The human papillomavirus type 18 E6 oncoprotein induces vascular endothelial growth factor 121 (VEGF121) transcription from the promoter through a p53-independent mechanism. Exp. Cell. Res. 313, 3239–3250 (2007).
Jain, R. K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58–62 (2005).
Stupp, R. et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10, 459–466 (2009).
Wen, P. Y. et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J. Clin. Oncol. 28, 1963–1972 (2010).
Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061–1068 (2008).
Batchelor, T. T. et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11, 83–95 (2007).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
D.A.R. has served as a consultant and receives honouraria from Amgen, Apogenix, EMD Serono, Genentech–Roche, Merck/Schering–Plough, Momenta Pharmaceuticals, Novartis and Stemline Therapeutics. P.Y.W. has served as a consultant and receives honouraria from Celldex, Genetech–Roche, Momenta Pharmaceuticals, Novartis and Sigma–Tau.
Rights and permissions
About this article
Cite this article
Reardon, D., Wen, P. Further delineating bevacizumab's response spectrum. Nat Rev Clin Oncol 11, 243–244 (2014). https://doi.org/10.1038/nrclinonc.2014.61
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2014.61
